ACET: Adicet Bio Inc. Consensus Target
Adicet Bio (ACET) is currently systematically utilizing its existing reserves, while significant seed capital fully covers current development costs for immunotherapeutic agents. The innovative T-cell method for combating lymphoma could provide the issuer with exceptional pricing power. The current figure is 28.94. This price chart complements data on the implementation of robotic bioreactors and AI sterility monitoring for gene therapy production.
Analytical breakdowns for Adicet Bio (ACET)
- stock value and consensus price forecast:
- market capitalization information:
- book value of equity indicators:
- debt obligations and liquidity statistics:
Aggregate Debt to Equity Adicet Bio|ACET - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital adicetbio.com|ACET - Company Aggregate Debts|Debts to Book Capitalization Adicet|ACET - Company Long-Term Debt|Company Short-Term Loans and Borrowings Adicet Bio|Quick Liquidity Indicator adicetbio.com
- earnings and multiples data:
ACET - Net Profit|Projected Future Earnings Adicet Bio|ACET - Price to Earnings Ratio|Future Price to Earnings Multiple adicetbio.com|ACET - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Adicet|ACET - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Adicet Bio|ACET - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months adicetbio.com|ACET - Net earnings per share growth this year|Earnings growth forecast for next year Adicet Bio
General company analysis:ACET Adicet Bio Inc.
Investors are assessing the resilience of Adicet Bio (ACET) by filtering out market noise using the average fair value calculated by leading analysts based on fundamental models. This consensus target price reflects a balance of capitalization expectations, accounting for critical expenses such as maintaining a cryogenic supply chain to preserve the viability of cell therapies during transport.
Competitors of Adicet Bio
Analyst Consensus Forecast argenx.com (ARGX)|Analyst Consensus Forecast BNTX (BioNTech)|ABVX - Consensus Target|ADMA Bio - Analyst Consensus Forecast|Average Forecast Price Protagonist Corp|IMVT (Immunovant, Inc.) - Consensus Target|KNSA: Analyst Forecast Prices|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|rapt.com (RAPT) - Average Forecast Price|Aerovate - Analyst Consensus Forecast|ACRS - Analyst Consensus Forecast|KYTX: Analyst Consensus Forecast|Broker Consensus Forecast TLSA|CABA (Cabaletta Bio) - Analyst Consensus Forecast|Ventyx Biosciences Inc. (VTYX) - Analyst Median Target|Analyst Consensus Forecast THTX|Consensus Target Avalo Therapeutics Inc AVTX|Analyst Consensus Forecast ELDN (Eledon Pharmaceuticals)|agenusbio.com (AGEN) - Average Forecast Price|CLYM: Consensus Target|zurabio.com - Analyst Forecast Prices|ATYR (aTyr) - Consensus Target|Adagene Inc. - Fair Value Consensus|IMA (ImageneBio) - Analyst Consensus Forecast|Price Target Chart STTK|Analyst Consensus Forecast EQ|Analyst Median Target connectbiopharm.com|Price Target Chart Immunic IMUX|Atara Biotherapeutics, Inc. (ATRA) - Average Forecast Price|InflaRx GmbH - Analyst Consensus Forecast|XFOR - Analyst Consensus Forecast|CELU: Analyst Consensus Forecast|Consensus Target INmune Bio Inc|BRNS (Barinthus Bio) - Analyst Consensus Forecast|Average Forecast Price Kezar Life Sciences Inc KZR|Consensus Target SABS (SAB Biotherapeutics)|Analyst Forecast Prices AKTX|Price Target Chart Enlivex Therapeutics Ltd. ENLV|QTTB (Q32 Bio Inc) - Forecast Levels Chart|GeoVax Labs Inc - Analyst Consensus Forecast|Fair Value Consensus EDSA (Edesa Biotech Corp)|IBIO: Analyst Consensus Forecast|Carisma Therapeutics Inc. (CARM) - Analyst Consensus Forecast|Price Target Chart XTL Biopharmaceuticals Ltd.|BOLT: Fair Value Consensus|Price Target Chart HCW Biologics Inc. (HCWB)|Consensus Target aptevotherapeutics.com APVO|Analyst Consensus Forecast AIM (AIM ImmunoTech)|Analyst Consensus Forecast Aditxt Inc. ADTX|GRI: Consensus Target|Fair Value Consensus XRTX (XORTX Therapeutics Inc)|HIND: Analyst Consensus Forecast|REVB - Analyst Median Target|Price Target Chart Indaptus Therapeutics|Consensus Target scinai.com (SCNI)|Price Target Chart CalciMedica, Inc. (CALI)|Consensus Target affimed.com AFMD|Allakos - Consensus Target|Analyst Consensus Forecast HOOKIPA Pharma, Inc. HOOK|IGMS - Price Target Chart|ITOS (iteostherapeutics.com) - Broker Consensus Forecast|OCEA: Analyst Consensus Forecast|Average Forecast Price TC BioPharm (Holdings) Plc (TCBP)|THRD (Third Harmonic Bio, Inc) - Analyst Consensus Forecast
